ATCOR Advances Clinical Trial Accessibility with Latest Power Partnership

The partnership between its ATCOR subsidiary and Power, a rapidly expanding patient recruitment marketplace that democratizes access to clinical trials for all patients, was just announced this Monday, February 6, by CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes.

The new collaboration will enable ATCOR and Power to carry out joint research and improve the accessibility to clinical trials and clinical research for underserved patients in the fields of diabetes mellitus, cardiovascular disorders, Alzheimer’s disease, and women’s health.

Reason for Collaboration

The introduction of fresh inclusion/exclusion criteria for patient screening across all clinical trial models, including traditional, hybrid, and decentralized models, is one of the partnership’s main objectives in order to improve patient access and patient diversity. An innovative strategy to benchmark the future of patient recruitment to improve patient reported outcomes will be made possible by the use of digital vascular biomarkers employing ATCOR’s SphygmoCor® technology in conjunction with the searchable patient searchable platform of Power.

ATCOR and Power will change the way people think about clinical trial diversity together. Starting with patient awareness of available clinical trials through Power’s user-friendly patient platform, patients can gain personalized access to medicines. ATCOR’s crucial digital vascular biomarkers for patient-centric screening are included in the improved protocol design, which results in a contemporary, holistic paradigm for inclusion/exclusion criteria across populations. To increase trust in the clinical trial process among various communities, the existing patient recruitment method must be changed. This requires both patient empowerment and patient-centric screening.

The Tech That Matters

A new medical device called “Pulse” from CardieX subsidiary CONNEQT will offer consumers improved artery health indicators from the convenience of their own homes. As a major decentralized clinical trial equipment that improves patient-centric screening and monitoring, Pulse was created. Any patient, anywhere can participate in clinical trials thanks to the Pulse. Customized patient recruitment is made possible by the Pulse’s use of digital vascular indicators in the procedure, which improves population variety.

To assist patients in finding therapeutic specialties that have importance for them personally, Power has developed an equal access and user-friendly recruitment tool. Making clinical trials accessible and taking into account the current socioeconomic, regional, and racial inequalities allows patients to choose and extends an offer to take part in the progress of medical science.

Message from the Executives

Toni R. Hofhine discusses his enthusiasm for working with Power to increase diversity in patient recruiting. The ATCOR Medical President notes that the relationship between ATCOR and Power presents a significant opportunity to advance diversity in clinical trials. The executive of the CardieX subsidiary thinks the agreement will make it possible for patients “everywhere” to participate equally in clinical research and use ATCOR’s digital vascular biomarkers to improve inclusion/exclusion standards.

To improve patient reported outcomes, underrepresented communities must be advanced. Craig Cooper, Group CEO of CardieX enterprises, describes the excitement of seeing the combined technology engage the patient across some of the most difficult areas in medical research. The ATCOR and Power relationship will increase patient diversity across all clinical trial models.

Brandon Li, a co-founder of Power, draws attention to the fact that expanding patient access is essential for enhancing patient representation in clinical research. He is equally aware, however, of the glaring lack of knowledge regarding the structural hurdles that frequently unintentionally exclude people of color. He expresses his joy at how Power’s most recent alliance with ATCOR is starting to eliminate some of these obstacles.

The Pulse device will be available for healthcare research and clinical trials in the coming months.

About Power

Patients who are interested in learning more about clinical trials frequently visit Power. For their unsolved problems, we make it simple for patients to locate and obtain cutting-edge medical research. Clinical trial sites can find interested patients who are looking for trials on our platform by using Power’s patient recruitment marketplace. Power makes it possible for all patients to have equal access to clinical trials by doing this.

For more information check out withpower.com.

About CardieX

CardieX (ASX:CDX), a health technology business with a listing on the Australian Securities Exchange, specializes in devices and treatments for the most widespread population health issues. Based on the company’s “gold standard” SphygmoCor® central blood pressure technology, its ATCOR subsidiary leads the globe in the monitoring of vascular biomarkers for clinical trials and health care research. The CONNEQT division of CardieX creates and sells wearables, digital solutions, and medical devices for remote patient monitoring, home health, and decentralized clinical trials.

Visit atcormedical.com and conneqthealth.com to learn more.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES